Alan G. Japp
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alan G. Japp has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
David E. Newby
British Heart Foundation/University Centre for Cardiovascular Science, University of Edinburgh, 49 Little France Crescent, Edinburgh, UK
3 shared publications- Ian L. Megson
Free Radical Research Facility, Division of Biomedical Sciences, University of the Highlands & Islands, Inverness, UK
2 shared publications A.D. Flapan
From the Department of Cardiology, Royal Infirmary of Edinburgh, Edinburgh, UK (A.G.J., N.L.C., N.v.G., J.M., A.D.F.); Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK (G.B., N.R.J., M.A.D., D.E.N.); and Department of Diabetes & Cardiovascular Science, UHI Millennium Institute, Inverness, UK (J.A., I.L.M.).
1 shared publicationAndrew D. Flapan
1 shared publicationArie Katz
Wyeth Research, Collegeville, PA
1 shared publicationD.E. Newby
From the Department of Cardiology, Royal Infirmary of Edinburgh, Edinburgh, UK (A.G.J., N.L.C., N.v.G., J.M., A.D.F.); Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK (G.B., N.R.J., M.A.D., D.E.N.); and Department of Diabetes & Cardiovascular Science, UHI Millennium Institute, Inverness, UK (J.A., I.L.M.).
1 shared publication
Latest Publications
- 1 March 2013
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 11 (3) , 285-287
Remodeling in heart failure: from the left ventricle to service delivery
Over the past three decades, advances in our understanding of heart failure pathophysiology have spurred the development of effective therapies for patients with heart failure and led to improved clinical outcomes. Further progress now requires increased provision of existing evidence-based therapies together with continued exploration of underlying pathogenic mechanisms and therapeutic targets. This was reflected at the 2012 Annual Autumn Meeting of the British Society for Heart Failure, attended by over 500 delegates from around the world with strong representation from all heart failure disciplines. The conference included a dedicated session on 'cardiac remodeling in left ventricular systolic dysfunction' as well as presentations on the latest evidence-based therapies in heart failure and aspects of service delivery within the UK.
- 1 March 2013
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 11 (3) , 285-287
Remodeling in heart failure: from the left ventricle to service delivery
Over the past three decades, advances in our understanding of heart failure pathophysiology have spurred the development of effective therapies for patients with heart failure and led to improved clinical outcomes. Further progress now requires increased provision of existing evidence-based therapies together with continued exploration of underlying pathogenic mechanisms and therapeutic targets. This was reflected at the 2012 Annual Autumn Meeting of the British Society for Heart Failure, attended by over 500 delegates from around the world with strong representation from all heart failure disciplines. The conference included a dedicated session on 'cardiac remodeling in left ventricular systolic dysfunction' as well as presentations on the latest evidence-based therapies in heart failure and aspects of service delivery within the UK.
- Open Access
- 23 January 2013
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 2 (1) , e006007
Effect of PSI‐697, a Novel P‐Selectin Inhibitor, on Platelet–Monocyte Aggregate Formation in Humans
Background: Platelet activation is central to the pathogenesis of acute coronary syndromes. Surface expression ofP‐selectin on activated platelets induces formation of platelet–monocyte aggregates and promotes vascular inflammation and thrombosis.P‐selectin antagonism may represent a novel therapeutic strategy in vascular disease. We aimed to investigate the effects of the novelP‐selectin antagonistPSI‐697 on platelet–monocyte aggregate formation in humans.Methods and Results: In a double‐blind, randomized, placebo‐controlled crossover study, healthy smokers were randomized to receive either oralPSI‐697 600 mg or matched placebo. The sequence of treatment was also randomized, with all subjects receiving bothPSI‐697 and placebo. Platelet–monocyte aggregates were measured by flow cytometry at 4 and 24 hours in the presence and absence of thrombin receptor‐activating peptide (TRAP; 0.1 to 1.0 μm/L). Theex vivoaddition ofTRAPcaused a concentration‐dependent increase in platelet–monocyte aggregates from 8.2% to 94.8% (PPP>0.05).P‐selectin‐blocking antibody (CLB‐Thromb6), but notPSI‐697, inhibited both stimulated and unstimulated platelet–monocyte aggregate formation in vitro (P<0.001).Conclusions: The novel small‐moleculeP‐selectin antagonistPSI‐697 did not inhibit basal or stimulated platelet–monocyte aggregate formation in humans at the dose tested. Its clinical efficacy remains to be established.Clinical Trial Registration: URL:http://EudraCT.ema.europa.euUnique identifier: 2007‐005695‐14.
- 23 January 2013
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 2 (1) , e006007
Open AccessEffect of PSI‐697, a Novel P‐Selectin Inhibitor, on Platelet–Monocyte Aggregate Formation in Humans
Background: Platelet activation is central to the pathogenesis of acute coronary syndromes. Surface expression ofP‐selectin on activated platelets induces formation of platelet–monocyte aggregates and promotes vascular inflammation and thrombosis.P‐selectin antagonism may represent a novel therapeutic strategy in vascular disease. We aimed to investigate the effects of the novelP‐selectin antagonistPSI‐697 on platelet–monocyte aggregate formation in humans.Methods and Results: In a double‐blind, randomized, placebo‐controlled crossover study, healthy smokers were randomized to receive either oralPSI‐697 600 mg or matched placebo. The sequence of treatment was also randomized, with all subjects receiving bothPSI‐697 and placebo. Platelet–monocyte aggregates were measured by flow cytometry at 4 and 24 hours in the presence and absence of thrombin receptor‐activating peptide (TRAP; 0.1 to 1.0 μm/L). Theex vivoaddition ofTRAPcaused a concentration‐dependent increase in platelet–monocyte aggregates from 8.2% to 94.8% (PPP>0.05).P‐selectin‐blocking antibody (CLB‐Thromb6), but notPSI‐697, inhibited both stimulated and unstimulated platelet–monocyte aggregate formation in vitro (P<0.001).Conclusions: The novel small‐moleculeP‐selectin antagonistPSI‐697 did not inhibit basal or stimulated platelet–monocyte aggregate formation in humans at the dose tested. Its clinical efficacy remains to be established.Clinical Trial Registration: URL:http://EudraCT.ema.europa.euUnique identifier: 2007‐005695‐14.
- Open Access
- 27 April 2010
- Published by Wolters Kluwer Health in Circulation
- Vol. 121 (16) , 1818-1827
Acute Cardiovascular Effects of Apelin in Humans
Background— Apelin, the endogenous ligand for the novel G protein–coupled receptor APJ, has major cardiovascular effects in preclinical models. The study objectives were to establish the effects of acute apelin administration on peripheral, cardiac, and systemic hemodynamic variables in healthy volunteers and patients with heart failure. Methods and Results— Eighteen patients with New York Heart Association class II to III chronic heart failure, 6 patients undergoing diagnostic coronary angiography, and 26 healthy volunteers participated in a series of randomized, double-blind, placebo-controlled studies. Measurements of forearm blood flow, coronary blood flow, left ventricular pressure, and cardiac output were made by venous occlusion plethysmography, Doppler flow wire and quantitative coronary angiography, pressure wire, and thoracic bioimpedance, respectively. Intrabrachial infusions of (Pyr 1 )apelin-13, acetylcholine, and sodium nitroprusside caused forearm vasodilatation in patients and control subjects (all P P =0.01) but not apelin ( P =0.3) or sodium nitroprusside ( P =0.9) was attenuated in patients with heart failure. Intracoronary bolus of apelin-36 increased coronary blood flow and the maximum rate of rise in left ventricular pressure and reduced peak and end-diastolic left ventricular pressures (all P 1 )apelin-13 (30 to 300 nmol/min) increased cardiac index and lowered mean arterial pressure and peripheral vascular resistance in patients and healthy control subjects (all P P Conclusions— Acute apelin administration in humans causes peripheral and coronary vasodilatation and increases cardiac output. APJ agonism represents a novel potential therapeutic target for patients with heart failure.
- 27 April 2010
- Published by Wolters Kluwer Health in Circulation
- Vol. 121 (16) , 1818-1827
Open AccessAcute Cardiovascular Effects of Apelin in Humans
Background— Apelin, the endogenous ligand for the novel G protein–coupled receptor APJ, has major cardiovascular effects in preclinical models. The study objectives were to establish the effects of acute apelin administration on peripheral, cardiac, and systemic hemodynamic variables in healthy volunteers and patients with heart failure. Methods and Results— Eighteen patients with New York Heart Association class II to III chronic heart failure, 6 patients undergoing diagnostic coronary angiography, and 26 healthy volunteers participated in a series of randomized, double-blind, placebo-controlled studies. Measurements of forearm blood flow, coronary blood flow, left ventricular pressure, and cardiac output were made by venous occlusion plethysmography, Doppler flow wire and quantitative coronary angiography, pressure wire, and thoracic bioimpedance, respectively. Intrabrachial infusions of (Pyr 1 )apelin-13, acetylcholine, and sodium nitroprusside caused forearm vasodilatation in patients and control subjects (all P P =0.01) but not apelin ( P =0.3) or sodium nitroprusside ( P =0.9) was attenuated in patients with heart failure. Intracoronary bolus of apelin-36 increased coronary blood flow and the maximum rate of rise in left ventricular pressure and reduced peak and end-diastolic left ventricular pressures (all P 1 )apelin-13 (30 to 300 nmol/min) increased cardiac index and lowered mean arterial pressure and peripheral vascular resistance in patients and healthy control subjects (all P P Conclusions— Acute apelin administration in humans causes peripheral and coronary vasodilatation and increases cardiac output. APJ agonism represents a novel potential therapeutic target for patients with heart failure.
- 1 May 2008
- Published by Elsevier in Biochemical Pharmacology
- Vol. 75 (10) , 1882-1892
The apelin–APJ system in heart failure
- 1 May 2008
- Published by Elsevier in Biochemical Pharmacology
- Vol. 75 (10) , 1882-1892
The apelin–APJ system in heart failure